The Markey Cancer Center (MCC), a dedicated matrix cancer center established as an integral part of the University of Kentucky (UK) and the UK Healthcare enterprise, has undergone dramatic expansion in recent years under the leadership of MCC Director Dr. B. Mark Evers. At this point in the center's development, the MCC seeks support through the National Cancer Institute (NCI) Cancer Center Support Grant to capitalize on this momentum and to drive a measurable reduction in cancer mortality in Kentucky, particularly Appalachian Kentucky, through a comprehensive program of cancer research, prevention, and patient care. The need for NCI Cancer Center designation is particularly acute in a state that leads the nation across numerous cancer indicators, including the highest rate of cancer deaths in the nation. Situated on a campus with all six health professions colleges in proximity to each other, the MCC offers a history of rich transdisciplinary collaboration, an outstanding program of cancer prevention and control that has produced seminal work in Appalachian Kentucky, nationally acclaimed basic research programs in cancer biology and DNA repair and oxidative stress, and a translational therapeutics program complemented by a top five College of Pharmacy. These strengths have coalesced in MCC's four thematic research programs: Cancer Cell Biology and Signaling; Cancer Prevention and Control; Drug Discovery, Delivery and Translational Therapeutics; and Redox Injury and Repair. Currently, the MCC's 108 Research and Associate Research members hold appointments in 24 departments in 7 colleges across the university (25 new faculty were recruited in the last 3 years). MCC members hold grants for 144 research projects funded in the annual composite (direct + indirect) amount of more than $30.5 million, of which over $11.3 million (37%) comes from the NCI. Accrual to therapeutic clinical trials has increased over 130% in three years, and MCC assignable space has increased 40%, including a doubling of state-of-the-art research space. In addition, six shared resources facilitate cutting-edge research by providing a robust infrastructure for specialized expertise and advanced methods. They include: Biospecimen and Tissue Procurement; Biostatistics; Cancer Research Informatics; Clinical Research and Data Management; Flow Cytometry and Cell Sorting; and Free Radical Biology in Cancer. The MCC is currently well positioned to take on new challenges and to continue to evolve in key strategic directions that take maximum advantage of these strengths.

Public Health Relevance

As a state with the second highest all-site cancer Incidence rate and the highest rate of cancer deaths in the United States, Kentucky suffers from particularly intractable cancer health challenges. The Markey Cancer Center seeks support to further develop its capacities in cutting-edge science to accelerate 'bench to bedside' translational outcomes, which will reduce this serious health disparity and significantly impact our patients, our state, and the nation through cancer prevention, patient care, and research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA177558-03S2
Application #
9129152
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ogunbiyi, Peter
Project Start
2013-07-08
Project End
2018-06-30
Budget Start
2015-09-01
Budget End
2016-08-31
Support Year
3
Fiscal Year
2015
Total Cost
$125,000
Indirect Cost
$41,944
Name
University of Kentucky
Department
Surgery
Type
Schools of Medicine
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Li, Jing; Song, Jun; Li, Xian et al. (2018) FFAR4 Is Involved in Regulation of Neurotensin Release From Neuroendocrine Cells and Male C57BL/6 Mice. Endocrinology 159:2939-2952
Rodriguez, Sharon D; Vanderford, Nathan L; Huang, Bin et al. (2018) A Social-Ecological Review of Cancer Disparities in Kentucky. South Med J 111:213-219
Chauhan, Aman; Yu, Qian; Ray, Neha et al. (2018) Global burden of neuroendocrine tumors and changing incidence in Kentucky. Oncotarget 9:19245-19254
Huang, Bin; Pollock, Elizabeth; Zhu, Li et al. (2018) Ranking composite Cancer Burden Indices for geographic regions: point and interval estimates. Cancer Causes Control 29:279-287
Rea, Matthew; Gripshover, Tyler; Fondufe-Mittendorf, Yvonne (2018) Selective inhibition of CTCF binding by iAs directs TET-mediated reprogramming of 5-hydroxymethylation patterns in iAs-transformed cells. Toxicol Appl Pharmacol 338:124-133
Yarana, Chontida; Carroll, Dustin; Chen, Jing et al. (2018) Extracellular Vesicles Released by Cardiomyocytes in a Doxorubicin-Induced Cardiac Injury Mouse Model Contain Protein Biomarkers of Early Cardiac Injury. Clin Cancer Res 24:1644-1653
Banerjee, Moumita; Cui, Xiaoyu; Li, Zhichuan et al. (2018) Na/K-ATPase Y260 Phosphorylation-mediated Src Regulation in Control of Aerobic Glycolysis and Tumor Growth. Sci Rep 8:12322
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
McKenna, Mary K; Noothi, Sunil K; Alhakeem, Sara S et al. (2018) Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia. Blood 131:2943-2954
Jones, Derek; Bopaiah, Jeevith; Alghamedy, Fatemah et al. (2018) Polypharmacology Within the Full Kinome: a Machine Learning Approach. AMIA Jt Summits Transl Sci Proc 2017:98-107

Showing the most recent 10 out of 359 publications